Development status: Active (as of 2022)

Combination therapy

Mechanism of Action/Target pathogen: DBOs bind reversibly to the beta-lactamase in the active site, inhibits class A, C, D beta-lactamases. No intrinsic antibacterial activity

Additional information: Synthetic compound. 2015 approved in fixed combination with ceftazidime. Orally available prodrug in clinical development, fixed combination with aztreonam in clinical development